Thermosensitive Liposomes for the Delivery of Cancer Therapeutics

Koning, Gerben A.; Li, Li; Hagen, Timo L.M. ten

doi:10.4155/tde.10.65

Cited by 8 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical experiments with DOX-loaded TSLs in association with local mild hyperthermia clearly reported an improved therapeutic effectiveness of temperature-triggered drug delivery (Kong et al 2000, Dromi et al 2007. These data revealed that the concentration of delivered chemotherapeutic compound in the tumor site depends on the nanoparticle's properties (e.g., plasma concentration of nanoparticles, drug-payload per liposome, kinetics of drug release) (Grull and Langereis 2012, Koning et al 2010, Hossann et al 2010, tumor parameters (e.g., tumoral vasculature and perfusion) (Blanco et al 2011) and the hyperthermia method (e.g., water-bath, microwave, radiofrequency and infrared radiations) (Poon and Borys 2009, Morita et al 2008, Huang et al 1994.…”

Section: Introductionmentioning

confidence: 99%

Focused ultrasound mediated drug delivery from temperature-sensitive liposomes: in-vitro characterization and validation

Escoffre

Novell

Smet³

et al. 2013

Phys. Med. Biol.

View full text Add to dashboard Cite

Nanomedicine-based delivery with non-invasive techniques is a promising approach to increase local drug concentration and to reduce systemic side effects. Focused ultrasound (FUS) has become a promising strategy for non-invasive local drug delivery by mild hyperthermia. In this study, traditional temperature-sensitive liposomes (TTSLs) encapsulating doxorubicin (DOX) were evaluated for FUS-mediated drug delivery with an in-vitro FUS setup. In-vitro studies showed quantitative release of the DOX from the lumen of the temperature-sensitive liposomes when heated to 42 °C with FUS using 1 MHz sinusoidal waves at 1.75 MPa for 10 min. No release was observed when heated at 37 °C. Moreover, we showed that DOX released from TTSLs by FUS is as efficiently internalized by glioblastoma cells as free DOX at 37 °C. In-vitro therapeutic evaluation showed that exposure of a cell monolayer to FUS-activated TTSLs induced a 60% and a 50% decrease in cell viability compared to cell medium and to TTSLs preheated at 37 °C, respectively. Using an in-vitro 3D cell culture model, the results showed that after FUS-mediated hyperthermia, preheated liposomes induced a 1.7-fold decrease in U-87 MG spheroid growth in comparison to the preheated liposomes at 37 °C. In conclusion, our results show that in-vitro FUS allows the evaluation of TTSLs and does not modify the cellular uptake of the released DOX nor its cytotoxic activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Focused ultrasound mediated drug delivery from temperature-sensitive liposomes: in-vitro characterization and validation

Escoffre

Novell

Smet³

et al. 2013

Phys. Med. Biol.

View full text Add to dashboard Cite

show abstract

“…According to previous studies, the phase transition of DPPC and DSPC phospholipid bilayer occurred at a temperature range of 39°C-42°C. 35,36 The lipid bilayer membrane of the LTCAs was broken, and the contents in the core of liposomes were leaked after irradiation. Meanwhile, due to the temperature increase, the generation of CO 2 bubbles by disintegration of NH 4 HCO 3 further accelerated the disruption of LTCAs.…”

Section: In Vitro Ltca Releasementioning

confidence: 99%

Near-infrared light-triggered theranostics for tumor-specific enhanced multimodal imaging and photothermal therapy

Wu¹,

Wang²,

Lu³

et al. 2017

IJN

View full text Add to dashboard Cite

The major challenge in current clinic contrast agents (CAs) and chemotherapy is the poor tumor selectivity and response. Based on the self-quench property of IR820 at high concentrations, and different contrast effect ability of Gd-DOTA between inner and outer of liposome, we developed “bomb-like” light-triggered CAs (LTCAs) for enhanced CT/MRI/FI multimodal imaging, which can improve the signal-to-noise ratio of tumor tissue specifically. IR820, Iohexol and Gd-chelates were firstly encapsulated into the thermal-sensitive nanocarrier with a high concentration. This will result in protection and fluorescence quenching. Then, the release of CAs was triggered by near-infrared (NIR) light laser irradiation, which will lead to fluorescence and MRI activation and enable imaging of inflammation. In vitro and in vivo experiments demonstrated that LTCAs with 808 nm laser irradiation have shorter T 1 relaxation time in MRI and stronger intensity in FI compared to those without irradiation. Additionally, due to the high photothermal conversion efficiency of IR820, the injection of LTCAs was demonstrated to completely inhibit C6 tumor growth in nude mice up to 17 days after NIR laser irradiation. The results indicate that the LTCAs can serve as a promising platform for NIR-activated multimodal imaging and photothermal therapy.

show abstract

“…In addition to inorganic materials, thermosensitive liposomes (TSLs) are also interesting instruments for drug delivery [24,47]. Liposomes are spherical vesicles composed of a membrane bilayer, usually constituted of phospholipids and an aqueous core [48].…”

Section: Introductionmentioning

confidence: 99%

Clinical Trials of Thermosensitive Nanomaterials: An Overview

et al. 2019

View full text Add to dashboard Cite

Currently, we are facing increasing demand to develop efficient systems for the detection and treatment of diseases that can realistically improve distinct aspects of healthcare in our society. Sensitive nanomaterials that respond to environmental stimuli can play an important role in this task. In this manuscript, we review the clinical trials carried out to date on thermosensitive nanomaterials, including all those clinical trials in hybrid nanomaterials that respond to other stimuli (e.g., magnetic, infrared radiation, and ultrasound). Specifically, we discuss their use in diagnosis and treatment of different diseases. At present, none of the existing trials focused on diagnosis take advantage of the thermosensitive characteristics of these nanoparticles. Indeed, almost all clinical trials consulted explore the use of Ferumoxytol as a current imaging test enhancer. However, the thermal property is being further exploited in the field of disease treatment, especially for the delivery of antitumor drugs. In this regard, ThermoDox®, based on lysolipid thermally sensitive liposome technology to encapsulate doxorubicin (DOX), is the flagship drug. In this review, we have evidenced the discrepancy existing between the number of published papers in thermosensitive nanomaterials and their clinical use, which could be due to the relative novelty of this area of research; more time is needed to validate it through clinical trials. We have no doubt that in the coming years there will be an explosion of clinical trials related to thermosensitive nanomaterials that will surely help to improve current treatments and, above all, will impact on patients’ quality of life and life expectancy.

show abstract

Thermosensitive Liposomes for the Delivery of Cancer Therapeutics

Cited by 8 publications

References 44 publications

Focused ultrasound mediated drug delivery from temperature-sensitive liposomes: in-vitro characterization and validation

Focused ultrasound mediated drug delivery from temperature-sensitive liposomes: in-vitro characterization and validation

Near-infrared light-triggered theranostics for tumor-specific enhanced multimodal imaging and photothermal therapy

Clinical Trials of Thermosensitive Nanomaterials: An Overview

Contact Info

Product

Resources

About